Jefferies Starts Oruka Therapeutics (ORKA) at Buy

Jefferies analyst Michael Yee initiates coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating and a price target of $40.00.

The analyst comments "We initiate ORKA at BUY and see high probability of success for two YTE modified "long-acting" enhanced antibodies for de-risked FDA approved IL23 and IL17 targets, i.e., Skyrizi and Bimzelx in $25-30B+ PsO markets. We see stock upside as co executes and reports impt PK data next year H2/25 as key catalyst. Prior published data suggests higher exposure of IL23 antibody could lead to much higher PASI-100 efficacy — a key bull case upside scenario as well."

For an analyst ratings summary and ratings history on Oruka Therapeutics click here. For more ratings news on Oruka Therapeutics click here.

Shares of Oruka Therapeutics closed at $29.62 yesterday.

You May Also Be Interested In

• Stifel: 'We are incrementally more constructive on TXN'
• Erste Group Downgrades The TJX Companies (TJX) to Hold
• TD Cowen Reiterates Buy Rating on Uber Inc. (UBER): 'Strong Delivery & Mobility Trends Continue'